Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

被引：396

作者：

Guagnano, Vito ^{[1
]}

Furet, Pascal ^{[1
]}

Spanka, Carsten ^{[1
]}

Bordas, Vincent ^{[1
]}

Le Douget, Mickael ^{[1
]}

Stamm, Christelle ^{[1
]}

Brueggen, Josef ^{[1
]}

Jensen, Michael R. ^{[1
]}

Schnell, Christian ^{[1
]}

Schmid, Herbert ^{[1
]}

Wartmann, Markus ^{[1
]}

Berghausen, Joerg ^{[1
]}

Drueckes, Peter ^{[1
]}

Zimmerlin, Alfred ^{[1
]}

Bussiere, Dirksen ^{[1
]}

Murray, Jeremy ^{[1
]}

Porta, Diana Graus ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2011年 / 54卷 / 20期

关键词：

HUMAN BREAST; MULTIPLE-MYELOMA; MYELOPROLIFERATIVE SYNDROME; ONCOGENE AMPLIFICATION; ACTIVATING MUTATIONS; GENE AMPLIFICATION; FGF FAMILY; INT-2; GENE; EXPRESSION; CANCER;

D O I：

10.1021/jm2006222

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

引用

页码：7066 / 7083

页数：18

共 61 条

[11] PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder [J].

Chen, J ;

DeAngelo, DJ ;

Kutok, JL ;

Williams, IR ;

Lee, BH ;

Wadleigh, M ;

Duclos, N ;

Cohen, S ;

Adelsperger, J ;

Okabe, R ;

Coburn, A ;

Galinsky, I ;

Huntly, B ;

Cohen, PS ;

Meyer, T ;

Fabbro, D ;

Roesel, J ;

Banerji, L ;

Griffin, JD ;

Xiao, S ;

Fletcher, JA ;

Stone, RM ;

Gilliland, DG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (40) :14479-14484

[12] Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 [J].

Chesi, M ;

Nardini, E ;

Brents, LA ;

Schrock, E ;

Ried, T ;

Kuehl, WM ;

Bergsagel, PL .

NATURE GENETICS, 1997, 16 (03) :260-264

[13] FGFR1 amplification in breast carcinomas:: a chromogenic in situ hybridisation analysis [J].

Elsheikh, Somaia Elbauomy ;

Green, Andrew R. ;

Lambros, Maryou B. K. ;

Turner, Nicholas C. ;

Grainge, Matthew J. ;

Powe, Des ;

Ellis, Ian O. ;

Reis-Filho, Jorge S. .

BREAST CANCER RESEARCH, 2007, 9 (02)

[14]

Fioravanti L, 1997, INT J CANCER, V74, P620, DOI 10.1002/(SICI)1097-0215(19971219)74:6<620::AID-IJC11>3.0.CO

[15]

2-9

[16]

Funahashi Y., 2002, Patent, Patent No. [WO200203

[17]

2872, 2002032872]

[18] Entry into a new class of protein kinase inhibitors by pseudo ring design [J].

Furet, Pascal ;

Caravatti, Giorgio ;

Guagnano, Vito ;

Lang, Marc ;

Meyer, Thomas ;

Schoepfer, Joseph .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (03) :897-900

[19]

Gavine P.R., 2011, AM ASS CANC RES AACR

[20]

Gómez-Román JJ, 2005, CLIN CANCER RES, V11, P459

← 1 2 3 4 5 6 7 →